Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability 3-09-2024, 19:00

Quantexa Partners with the Anti-Human Trafficking Intelligence Initiative (ATII) to Intensify the Fight Against Human Trafficking 11-01-2024, 18:00

Scott Parnell Improves Customer Experience, Productivity and Delivery Sustainability with Descartes’ Electronic Proof of Delivery 18-06-2024, 17:45